Semaglutid 5mg

▎ Enzimba ya Semaglutid

▎ Okunoonyereza ku Semaglutid

Ensibuko y’okunoonyereza ku Semaglutid eri etya?

Semaglutid ye peptide-1 (GLP-1) analogue eringa glucagon y’omuntu, eri mu kibinja ky’eddagala eriziyiza GLP-1 receptor agonist. GLP-1 busimu obubeera mu butonde obufulumizibwa obutoffaali bw’ekyenda oluvannyuma lw’okulya, obuyamba okufulumya insulini n’okuziyiza okufulumya glucagon okutereeza emiwendo gya glucose mu musaayi. Enkulaakulana ya Semaglutid yasibuka mu kunoonyereza okw’obwegendereza ku mirimu gy’omubiri gya GLP-1. GLP-1 erina ekitundu ky’obulamu ekitono mu mubiri, eddakiika nga 1-2, kuba kyangu okuvunda olw’enziyiza za dipeptidyl peptidase-4 (DPP-4) mu mubiri. Okuvvuunuka obuzibu buno, bannassaayansi baakyusa ensengekera ya GLP-1, ne baleeta enkyukakyuka za amino asidi ezenjawulo era ne bongerako ebibinja ebikuuma okutumbula obuziyiza bwayo eri enziyiza za DPP-4, bwe batyo ne bawangaaza ebbanga lyayo ly’ekola mu mubiri ^[1] . Mu nsengekera ya Semaglutid, alanine mu kifo 8 ekyusiddwamu α-aminoisobutyric acid (Aib), ekitakoma ku kulongoosa butebenkevu bwa ddagala wabula era kyongera ku maanyi gaalwo ag’okusiba n’ebikwata GLP-1 ^[2] . Olujegere olw’enjawulo olw’amasavu olw’ebbali lwongerwa ku C-terminus ya Semaglutid, eyungibwa ku bisigalira bya lysine okuyita mu γ-glutamine, ekyongera okwongera ku kitundu ky’obulamu bw’eddagala lino n’okulisobozesa okufuyirwa omulundi gumu mu wiiki oba okumira mu kamwa omulundi gumu olunaku ^[1] . Semaglutid yasooka kukolebwa nga yesigamye ku kunoonyereza n’okukyusa GLP-1 ey’obutonde, nga kigendereddwamu okuwa obujjanjabi obusingako obulungi eri abalwadde abalina enkyukakyuka y’omubiri ey’ekika kya 2 ^{[1, 2]} . Okuyita mu bino structural optimizations, Semaglutid tekoma ku kusigaza physiological activity ya GLP-1 naye era erongoosa nnyo pharmacokinetic properties zaayo, okufuuka long-acting GLP-1 receptor agonist of important clinical value. Okukola Semaglutid kituukiddwako kinene, okuleeta enkola empya ez’obujjanjabi eri abalwadde abalina enkyukakyuka y’omubiri ey’ekika eky’okubiri. Nga elongoosa ensengekera ya GLP-1 ey’obutonde, evvuunuka obuzibu bw’ekitundu ky’obulamu bwayo obutono era n’elongoosa obutebenkevu bw’eddagala n’obudde bw’okukola.

Enkola ya Semaglutid ekola ki?

Semaglutid ye glucagon-like peptide-1 (GLP-1) receptor agonist ekola ebbanga eddene, era enkola yaayo ey’okukola okusinga etuukibwako okuyita mu bintu bino wammanga:

Okulungamya glucose mu musaayi:

Semaglutid ye ddagala eriweweeza ku bulwadde bwa GLP-1 receptor agonist (GLP-1RA). Enkola yaayo enkulu kwe kuziyiza okwegomba emmere ng’eziyiza okwagala okulya, okukendeeza ku kwettanira emmere erimu amasavu amangi, n’okukyusakyusa ekifo awaweebwa emmere mu hypothalamic okukendeeza ku mmere gye balya. Era kyongera okukkuta, kilwawo okufulumya amazzi mu lubuto, n’okukendeeza ku kutambula kw’olubuto, bwe kityo ne kituuka ku kugejja. Okukendeeza ku buzito kuno kwongera ku kuwulira kwa insulini era kuyamba okutereeza emiwendo gya glucose mu musaayi ^[3] . Semaglutid ereeta okugejja mu biwuka okuyita mu makubo g’obusimu agasaasaanyiziddwa. Okunoonyereza kulaga nti ekola ku kikolo ky’obwongo, septal nucleus, ne hypothalamus naye nga tesalako kiziyiza kya musaayi n’obwongo. Wabula, ekwatagana n’obwongo ng’eyita mu bitundu by’omubiri ebiyitibwa circumventricular organs ne ventricular-proximal areas. Semaglutid ekola c-Fos mu bitundu by’obwongo kkumi, omuli ebitundu by’obwongo obw’emabega ebigendereddwa butereevu n’ebitundu eby’okubiri nga lateral parabrachial nucleus awatali nkolagana ya GLP-1R butereevu. Okwekenenya okw’otoma kulaga nti okukola kuzingiramu obusimu obuyitibwa lateral parabrachial nucleus neurons obufuga okukomya emmere, bwe kityo ne kitereeza glucose mu musaayi ^[4]. .

Enteekateeka y’olubuto n’ekyenda:

Semaglutid ekola ku bikwata GLP-1 mu byenda, ng’ekozesa ekkubo ly’obusimu bwa vagus okukyusa entambula y’olubuto n’ekyenda. Kiziyiza okukonziba kw’omumwa gwa nnabaana, kinyweza okusika omuguwa kw’omusuwa gw’omu lubuto, n’okuwangaaza okusigala kw’emmere mu lubuto, okulwawo okuyingira mu nnywanto n’okuziyiza okulinnya kwa glucose mu musaayi oluvannyuma lw’okulya, ekivaamu emiwendo egy’okutebenkera ^[5] . Okugatta ku ekyo, Semaglutid ekosa ebitundu ebikwata GLP-1 eby’omu makkati naddala mu hypothalamic arcuate ne paraventricular nuclei. Kiziyiza ensonga ezisitula okwagala okulya nga neuropeptide Y (NPY) ne agouti-related protein (AgRP), ate nga ekola obusimu bwa proopiomelanocortin (POMC) okutumbula okufulumya obusimu obusitula alpha-melanocyte (α-MSH) ^[5] . Ebikolwa bino bireetera omuntu okukkuta, bikendeeza enjala, n’okukendeeza ku mmere, ne biyamba okufuga omugejjo n’okulongoosa mu ngeri etali ya butereevu okufuga sukaali mu musaayi.

Obukuumi bw’emisuwa gy’omutima:

Semaglutid etumbula okufulumya nitric oxide (NO) n’ebirungo ebirala ebigaziya emisuwa okuva mu butoffaali bw’emisuwa, okutumbula okugaziwa kw’emisuwa n’okutambula kw’omusaayi. Era kiziyiza okuzimba n’okunyigirizibwa kw’okwokya (oxidative stress), ekikendeeza ku kwonooneka kw’endothelial n’obulabe bw’okuzimba emisuwa. Nga kiziyiza okwagala okulya n’okulya emmere, kiyamba okugejja, kitereeza enkyukakyuka y’amasavu, kikendeeza ku triglycerides ne low-density lipoprotein cholesterol (LDL-C), n’okulinnyisa high-density lipoprotein cholesterol (HDL-C). Ekirala, kiyinza okuganyula puleesa nga kikyusakyusa enkola y’omusaayi gw’ekibumba n’enkola y’obusimu, okukendeeza ku bulabe bwa puleesa n’okukendeeza ku nsonga ezireeta endwadde z’emisuwa ^[6]. .

Semaglutid n’okulungamya okuwandiika kw’okukyusa WAT ​​okudda mu BAT n’okukola kwa BAT.

Ensibuko: PubMed ^{[13] .}

Ebikulu ebigezesa n’okunoonyereza

Mu nsonga z’okukola ensengekera y’eddagala n’okulongoosa, mu kiseera ky’okukola semaglutide, enkola y’okusiba okuddamu ku albumin yakwatibwako okwongera ku bbanga ly’okukola kw’eddagala. Nga tusalawo omugatte ogusinga obulungi ogwa asidi z’amasavu n’ebiyungo, obusobozi bw’okusiba ku albumin bwasukkiridde ate nga tukuuma obulungi ku GLP-1 receptor (GLP-1R) (Knudsen LB, 2019).

Mu nsonga y’okukozesa eddagala, semaglutide alina ebikolwa eby’okugejja eby’ekika ekya waggulu. Semaglutid ye glucagon-like peptide-1 receptor agonist (GLP-1 RA) nga erina ekitundu ky’obulamu ekiwanvu eky’okuggyawo, ekisobozesa okukuba empiso wansi w’olususu buli wiiki. Enkola yaayo ey’okugejja yeewuunyisa. Mu balwadde abalina ekika kya 2 metabolism (T2DM), okukuba empiso ya semaglutide wansi w’olususu buli wiiki kirabika nga kikola bulungi mu kugejja okusinga GLP-1RA endala eza buli wiiki. Mu kugezesebwa okwa phase II okuzuula ddoozi eri abalwadde abagejjulukuka abatalina T2DM, empiso ya semaglutide omulundi gumu buli lunaku wansi w’olususu yali nnungi nnyo mu kugejja okusinga placebo n’omulundi gumu buli lunaku 3.0mg liraglutide. Okugejja okuva ku semaglutide mu kunoonyereza kuno kwasukka omutindo gw’eddagala eriweweeza ku mugejjo ogwateekebwawo ekitongole ky’eddagala ekya Bulaaya (EMA) n’ekitongole kya Amerika ekivunaanyizibwa ku by’emmere n’eddagala (FDA), nga tewali nsonga ya bukuumi, ekiraga nti empiso ya semaglutide omulundi gumu buli lunaku wansi w’olususu erina obusobozi okubeera eddagala erikendeeza ku mugejjo mu biseera eby’omu maaso ^[7]. .

Semaglutid asobola okulongoosa enkola y’omutima era akozesebwa mu kujjanjaba endwadde z’emisuwa. Ebyavudde mu kugezesebwa kwa STEP-HFpEF byalangirirwa, nga mu kino eddagala eritta ssukaali eriringa peptide 1 agonist semaglutide erya ddoozi ennene lyalongoosa nnyo obubonero bw’okulemererwa kw’omutima n’ekitundu ekikuumibwa ejection fraction (HFpEF) n’okukendeeza ku miwendo gya N-terminal pro-B-type natriuretic peptide (NT-proBNP). Okunoonyereza kuno kwagezesa enkola y’obujjanjabi bwa acute semaglutide ku bitundu by’emisuwa ebya ddyo ebyawuddwamu era ne kuzuula nti semaglutide yayongera okusika omuguwa kw’emisuwa gy’emisuwa gy’omuntu emirundi egisukka mu esatu mu ngeri eyeesigama ku ddoozi, awatali kwongera ku mpisa ya arrhythmias. Ekikolwa kino kisinga kuva ku kweyongera kw’okutwala Ca2+ mu sarcoplasmic reticulum. Obujjanjabi bwa semaglutide obwa dose ennene mu balwadde abalemererwa omutima busobola okulongoosa enkola y’emisuwa era bwe kityo ne bukendeeza ku bubonero ^[8]. .

Semaglutid enoonyezebwa okujjanjaba obulwadde bwa steatohepatitis obutali bwa mwenge (NASH). Enteekateeka yaayo entuufu ekoze kinene mu kulongoosa okufuga glucose mu musaayi, obuzito, puleesa, lipids, β-cell function, n’enkola y’emisuwa mu balwadde abalina type 2 metabolism. Ekirala, okukola eddagala eriweebwa mu kamwa erya semaglutide kiyinza okuwa emigaso emirala eri abalwadde mu nsonga z’okugoberera obujjanjabi ^[9]. .

Enjawulo mu bikolwa bya Semaglutid mu kugejja mu bantu

Ebiva mu kugejja mu bantu abakulu abalina obulwadde bw’emisuwa n’emisuwa obuliwo, omugejjo oba omugejjo nga tebalina Metabolism: 

Mu kugezesebwa kwa SELECT cardiovascular outcomes, semaglutide yakendeeza ku big adverse cardiovascular events (MACE) ne 20% mu bantu abakulu 17,604 abalina obulwadde bw’emisuwa n’emisuwa obuliwo, omugejjo oba omugejjo, era nga tebalina metabolism ^[10] . Mu kwekenneenya kuno okwalagirwa nga tekunnabaawo, abanoonyereza beekenneenya ebikolwa bya semaglutide ku buzito, ebiva mu anthropometric, obukuumi, n’okugumiikiriza okusinziira ku baseline body mass index (BMI). Abalwadde abafuna semaglutide baafuna okugejja okumala ebbanga mu wiiki 65, ne basigala nga bagejja okutuuka ku myaka 4. Ku wiiki 208, semaglutide yaleetawo okukendeera okunene ennyo mu kigero mu buzito (-10.2%), okwetooloola ekiwato (-7.7 cm), n’omugerageranyo gw’ekiwato n’obuwanvu (-6.9%) bw’ogeraageranya ne placebo (-1.5%, -1.3 cm, ne -1.0%, respectively; okugeraageranya kwonna kwali kwa maanyi mu bibalo. Clinically meaningful weight loss occurred across abasajja n’abakazi, amawanga gonna, ebika by’omubiri, n’ebitundu Semaglutid yali ekwatagana n’ebizibu eby’amaanyi ebitono Ku buli kibinja kya BMI (<30, 30 okutuuka ku <35, 35 okutuuka ku <40, ne ≥40 kg/m²), semaglutide yalina ebizibu eby’amaanyi ebya wansi (ebibaddewo ku buli muntu-emyaka 100: 43.23,. 43.54, 51.07, ne 47.06 vs. 50.48, 49.66, 52.73, ne 60.85 ku placebo). okulongoosa mu anthropometric bw’ogeraageranya ne placebo ku wiiki 208, ng’okugejja kwawangaala okumala emyaka 4.

Ebiva mu kugejja mu bantu abagejjulukuka oba abagejjulukuka abatalina Metabolism:  

Okwekenenya okutegekeddwa kwekenneenya obulungi n’obukuumi bwa semaglutide mu bantu abagejjulukuka oba abagejjulukuka abatalina metabolism ^[11] . Okuddamu okwetegereza kuno kwagatta ebivudde mu kugezesebwa okw’obujjanjabi okungi, nga kulaga enkosa ya semaglutide ku kugejja, ebipimo by’enkyukakyuka y’emmere, n’ebiva mu bulamu okutwalira awamu. Ebizuuliddwa biraga nti semaglutide yali ekwatagana n’okugejja ennyo n’okulongoosa mu bipimo by’obulamu ebikwatagana n’omugejjo, ekiraga obusobozi bwayo ng’enkola ey’omuwendo ey’obujjanjabi eri abalwadde abagejjulukuka. 

Ebiva mu kugejja mu balwadde abatali ba ssukaali (Obujulizi okuva mu RCT eziwera): 

Okugezesebwa kuna okufugibwa (RCTs) okwali kuzingiramu abalwadde abalina obuzito obusookerwako obwa kkiro 96–105 kwekenneenya buli wiiki 2.4 mg subcutaneous semaglutide nga kwogasse n’okuyingira mu bulamu (okubuulirira, emmere, okukola emirimu gy’omubiri) okugejja ^[12] . RCT emu mu balwadde abatali ba ssukaali (N = 1,961) yategeeza nti omugejjo gwakendeera ebitundu 15% (kkiro 15) okusinziira ku 2% (kkiro 3) nga bakozesa placebo oluvannyuma lwa wiiki 68 (statistically significant). Ekitundu ky’abalwadde abatuuka ku kugejja ≥5% kyali 86% vs. 32% (omuwendo ogwetaagisa okujjanjaba [NNT] = 2), ate ≥10% okugejja gwali 69% vs. 12% (NNT = 2). Okugejja kwa plateaued ku ~60 weeks. Ebizibu by’omu lubuto (AEs) byaliwo mu 74% vs. 48% (omuwendo ogwetaagisa okukola obulabe [NNH] = 3). Okuyimirizaawo olw’AEs kwali 7% vs. 3% (NNH = 25). Ebivuddemu ebifaanagana byalabibwa mu RCT endala nga waliwo okuyingira mu bulamu obw’amaanyi (N = 611): semaglutide yaleeta okugejja ebitundu 16% (kkiro 17) okusinziira ku 6% (kkiro 6). Mu RCT ey’okunoonyereza ku ddoozi mu balwadde abatali ba ssukaali (N = 1,210), buli wiiki 2.4 mg semaglutide, 1.0 mg semaglutide, oba placebo yavaamu okugejja okwa wakati okwa 10%, 7%, ne 3% oluvannyuma lwa wiiki 68. Ebitundu ebituuka ku kugejja ≥5% byali 69% (2.4 mg), 57% (1.0 mg), ne 29% (placebo). Ku 2.4 mg vs. 1.0 mg, NNT = 9. AE profiles zaali zifaanagana mu dose zonna. Mu RCT y’okukuuma obuzito (N = 803), abeetabye mu kugezesebwa abatali balwadde ba ssukaali baafuna 2.4 mg semaglutide buli wiiki okumala wiiki 20, oluvannyuma ne balondebwa mu ngeri ey’ekifuulannenge okugenda mu maaso ne semaglutide oba okukyusa okudda ku placebo. Oluvannyuma lwa wiiki 48, abagenda mu maaso n’okukozesa semaglutide baafiirwa ebitundu 8% okusinziira ku bakozesa placebo ne bafuna ebitundu 7%. 

Mu bufunze, semaglutide ye GLP-1 receptor agonist nga erina omuwendo gw’okukozesa mu bitundu ebingi. Mu bujjanjabi bw’enkyukakyuka mu mubiri, yeekwata ku bikwata GLP-1 okutumbula okufulumya insulini n’okuziyiza okufulumya glucagon, okufuga obulungi emiwendo gya glucose mu musaayi n’okuwa eky’obujjanjabi eky’amaanyi eri abalwadde abalina enkyukakyuka y’omubiri ey’ekika eky’okubiri. Mu by’obujjanjabi bw’omugejjo, semaglutide esobola okukendeeza ennyo ku maanyi agayingira ng’ayita mu nkola nga okuziyiza okulya emmere mu makkati n’okulwawo okufulumya amazzi mu lubuto, okuyamba abalwadde abagejjulukuka okugejja n’okulongoosa embeera y’omubiri gwabwe. Okugatta ku ekyo, semaglutide eraga essuubi eriyinza okukozesebwa mu kuziyiza n’okujjanjaba endwadde z’emisuwa, era okulongoosa kwayo ensonga z’obulabe eri emisuwa n’emisuwa kiwa enkola empya okukendeeza ku bikolwa by’emisuwa. Okujja kwa semaglutide tekukoma ku kugaggawaza nkola za bujjanjabi ku ndwadde ezikwatagana naye era kuleeta essuubi eppya ery’okutumbula omutindo gw’obulamu n’obulamu bw’abalwadde.

Ebikwata ku Muwandiisi

Ebintu ebyogeddwako waggulu byonna binoonyerezeddwako, birongooseddwa era ne bikung’aanyizibwa kkampuni ya Cocer Peptides.

Omuwandiisi wa Scientific Journal

Hegner P munoonyereza mu yunivasite y’e Regensburg. Omulimu gwe gukwata ku Chemistry, Cardiovascular System, ne Cardiology. Mu Chemistry, anoonyereza ku reactions ezisibiddwa ku bulamu bw’emisuwa n’emisuwa. Mu kunoonyereza ku nkola y’emisuwa gy’omutima, anoonyereza ku nkola y’omutima n’emisuwa, ng’anoonya amagezi agakwata ku bujjanjabi. Okunoonyereza kwe ku Cardiology kusinga kukwata ku kuziyiza endwadde z’omutima, okuzuula n’okuzijjanjaba.

Ebintu Hegner by’akola bikulu nnyo. Okutegeera kwe okw’eddagala kuleetedde okukola eddagala eppya ery’emisuwa. Omulimu gwe ku nkola y’omutima n’emisuwa guyongedde okutegeera endwadde z’emisuwa. Mu bujjanjabi, okunoonyereza kwe kulongoosezza enzirukanya y’endwadde z’omutima, ne kusitula omutindo gw’okulabirira abalwadde. Okutwaliza awamu, enkola ya Hegner ey’eby’emikono mingi egaggawaza eddagala ly’emisuwa n’emisuwa, n’ewa essuubi okukendeeza ku buzito bw’endwadde n’ebiva mu balwadde ebirungi. Hegner P awandiikiddwa mu kiwandiiko ekijuliziddwa mu kiwandiiko ekijuliziddwa [8].

▎ Ebiwandiiko Ebikwatagana

[1] Memon A, Tehrim M, Kumari B. Semaglutid: enkya empya eri abalwadde ba ssukaali[J]. Journal of ekibiina ekigatta abasawo mu Pakistan, 2023,73 (3): 721.DOI: 10.47391 / JPMA.7558.

[2] Ma H, Huang W, Wang X, n’abalala. Okutegeera enzimba mu kukola kwa GLP-1R nga agonist ya molekyu entono[J]. Okunoonyereza ku butoffaali, 2020,30 (12): 1140-1142.DOI: 10.1038 / s41422-020-0384-8.

[3] Kim HS, Jung C H. Semaglutid ey’omu kamwa, Agonist esooka okuyingizibwa mu Glucagon-Like Peptide-1 Receptor: Kyandiba Essasi ly’Obulogo eri ekika kya 2 Metabolism?[J]. Ekitabo ky’ensi yonna ekya Sayansi wa Molekyulu, 2021,22 (18).DOI:10.3390/ijms22189936.

[4] Gabery S, Salinas CG, Paulsen SJ, n’abalala. Semaglutid ekendeeza ku buzito bw’omubiri mu biwuka ng’eyita mu makubo g’obusimu agasaasaanyiziddwa[J]. Jci Okutegeera, 2020,5 (6).DOI: 10.1172 / jci.okutegeera.133429.

[5] Katsurada K, Yada T. Ebikolwa by’obusimu eby’ekyenda n’obwongo ebiva mu glucagon-like peptide-1 ne receptor agonist yaayo[J]. Journal of Okunoonyereza ku nkyukakyuka y'ebirungo, 2016,7:64-69.DOI:10.1111/jdi.12464.

[6] Ryan D. H., Lingvay I, Colhoun HM, n’abalala. Ebikolwa bya Semaglutid ku biva mu misuwa gy’omutima mu bantu abagejjulukuka oba abagejjulukuka (SELECT) rationale and design[J]. Ekitabo ky’omutima gw’Amerika, 2020,229:61-69.DOI:10.1016/j.ahj.2020.07.008.

[7] Christou G. A., Katsiki N., Blundell J., n’abalala. Semaglutid nga eddagala erisuubiza eriziyiza omugejjo[J]. Okuddamu okwetegereza omugejjo, 2019, 20 (6): 805-815.DOI: 10.1111 / obr.12839.

[8] Hegner P, Seitz S, Schopka S, n’abalala. Semaglutid erongoosa enkola y’okukonziba mu atrium y’omuntu eyeetongodde[J]. Ekitabo ky’omutima ekya Bulaaya, 2024,45.DOI:10.1093/eurheartj/ehae666.3729.

[9] Knudsen LB, Lau J. Okuzuula n’okukulaakulanya Liraglutide ne Semaglutid[J]. Ensalo mu by’obutonde bw’ensi, 2019,10.DOI:10.3389/fendo.2019.00155.

[10] Ryan D. H., Lingvay I, Deanfield J., n’abalala. Ebikolwa by’okugejja okumala ebbanga eddene ebya semaglutide mu mugejjo awatali kukyusakyusa mu mubiri mu kugezesebwa kwa SELECT[J]. Eddagala ly’obutonde, 2024, 30 (7): 2049-2057.DOI: 10.1038 / s41591-024-02996-7.

[11] Alanazi M, Alshahrani J. A., Aljaberi A. S., n’abalala. Effect of Semaglutid mu bantu abalina omugejjo oba abagejjulukuka nga tebalina Metabolism[J]. Cureus Journal of Sayansi w'Ebyobujjanjabi, 2024,16 (8).DOI: 10.7759 / cureus.67889.

[12] Ojeniran M, Dube B, Paige A, n’abalala. Semaglutid okugejja[J]. Omusawo w’amaka mu Canada, 2021,67 (11): 842.DOI: 10.46747 / cfp.6711842.

[13] Papakonstantinou I, Tsioufis K, Katsi V. Okussa essira ku nkola y’okukola kwa Semaglutid[J]. Ensonga eziriwo mu kiseera kino mu molekyu biology, 2024,46 (12): 14514-14541.DOI: 10.3390 / cimb46120872.

EBINTU BYONNNA N’AMAWULIRE GW’EBINTU EBIweereddwa KU MUTINDO GUNO BIKOZESEBWA KU KUSASANYA AMAWULIRE N’EBIKOLWA BY’OKUSOMESA BYOKKA.  

Ebintu ebiweereddwa ku mukutu guno bigendereddwamu kunoonyereza mu kisenge (in vitro research) byokka. Okunoonyereza mu kisenge (in vitro research) (Olulattini: *mu ndabirwamu*, ekitegeeza mu bikozesebwa mu ndabirwamu) kukolebwa ebweru w’omubiri gw’omuntu. Ebintu bino si bya ddagala, tebikkiriziddwa kitongole kya Amerika ekivunaanyizibwa ku by’emmere n’eddagala (FDA), era tebirina kukozesebwa kuziyiza, kujjanjaba oba kuwonya mbeera yonna ya bujjanjabi, bulwadde oba bulwadde. Kikugirwa nnyo mu mateeka okuyingiza ebintu bino mu mubiri gw’omuntu oba ebisolo mu ngeri yonna.